AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10412580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological method at the presurgery stage
Number of subjects: 200
Study 7623991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 14
Study 7623991 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ACEi) - 10 mg enalapril o.d.
Number of subjects: 14
Study 7623991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LPD and ACEi
Number of subjects: 14
Study 2187519 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex scanning
Number of subjects: 29
Study 2187519 — intervention group
Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 29
Study 7069070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal breathing
Number of subjects: 14
Study 7069070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral breathing
Number of subjects: 14
Study 7069070 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 14
Study 31465842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological rhythm control
Number of subjects: 0
Study 31465842 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane-active antiarrhythmic drugs
Number of subjects: 0
Study 31465842 — intervention group
Group type: EXPERIMENTAL
Intervention: Stricter rate control (target rate <80/min)
Number of subjects: 0
Study 31465842 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of long-standing AF
Number of subjects: 0
Study 31465842 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulation with non-vitamin K-antagonist oral anticoagulants
Number of subjects: 0
Study 30910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive interactive neurostimulation (NIN) therapy
Number of subjects: 61
Study 30910488 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 61
Study 28987768 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab Q2W
Number of subjects: 776
Study 28987768 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab Q3W
Number of subjects: 776
Study 28987768 — intervention group
Group type: COMPARATOR
Intervention: ipilimumab
Number of subjects: 776
Study 25824327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (anti-VEGF drugs) administered as needed over a 2-year period.
Number of subjects: 1115
Study 25824327 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with VMT or VMA at baseline
Number of subjects: 1115
Study 25824327 — intervention group
Group type: COMPARATOR
Intervention: Eyes without VMT or VMA at baseline
Number of subjects: 1115
Study 23818591 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based training program
Number of subjects: 141
Study 23818591 — intervention group
Group type: COMPARATOR
Intervention: Head Start alone
Number of subjects: 141
Study 23818591 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 141
Study 21091083 — intervention group
Group type: EXPERIMENTAL
Intervention: FOX (Fitting to Outcomes eXpert) software tool for programming cochlear implant processors
Number of subjects: 8
Study 20003019 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time adenosine myocardial contrast echocardiography (MCE) using Sonovue and power pulse inversion (ATL 5000) at rest and during adenosine stress
Number of subjects: 76
Study 17433319 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian fenestration and coagulation (group 1)
Number of subjects: 65
Study 17433319 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy (group 2)
Number of subjects: 65
Study 17433319 — intervention group
Group type: COMPARATOR
Intervention: Normal ovaries
Number of subjects: 65
Study 17144778 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral self help for depression
Number of subjects: 0
Study 15542165 — intervention group
Group type: EXPERIMENTAL
Intervention: WF10 therapy (0.5 ml/kg body weight, diluted in physiological saline or 5% dextrose water, intravenous infusions over 2 h on 5 consecutive days, every 3 weeks for 2 cycles)
Number of subjects: 100
Study 15542165 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (control group)
Number of subjects: 100
Study 11103099 — intervention group
Group type: EXPERIMENTAL
Intervention: ipriflavone-containing supplement
Number of subjects: 7
Study 11103099 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 8956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-positive, coagulase-negative micrococci
Number of subjects: 394
Study 8956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus
Number of subjects: 394
Study 8956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococci
Number of subjects: 394
Study 8956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococci
Number of subjects: 394
Study 8956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-negative organisms
Number of subjects: 394
Study 8956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive gram stain or infection with species other than gram-positive, coagulase-negative micrococci
Number of subjects: 394
Study 8956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial presenting visual acuity
Number of subjects: 394
Study 8956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial growth from vitrectomy cassette specimen
Number of subjects: 394
Study 1550223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33 IU/h AVP
Number of subjects: 20
Study 1550223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.66 IU/h AVP
Number of subjects: 20
Study 1550223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.99 IU/h AVP
Number of subjects: 20
Study 1550223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4039118 — intervention group
Group type: EXPERIMENTAL
Intervention: aztreonam-clindamycin
Number of subjects: 80
Study 4039118 — intervention group
Group type: COMPARATOR
Intervention: tobramycin-clindamycin
Number of subjects: 80
Study 31426869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-it-forward arm (free gonorrhea and chlamydia testing with donation option)
Number of subjects: 300
Study 31426869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-what-you-want arm (free testing with payment option after receiving the test)
Number of subjects: 300
Study 31426869 — intervention group
Group type: COMPARATOR
Intervention: Standard of care arm (full price for dual gonorrhea and chlamydia testing)
Number of subjects: 300
Study 31426869 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 300
Study 28841892 — intervention group
Group type: EXPERIMENTAL
Intervention: Price reduction on fruits and vegetables (FV)
Number of subjects: 642
Study 28841892 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-building
Number of subjects: 642
Study 28841892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined skill-building and price reduction
Number of subjects: 642
Study 28841892 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 642
Study 26113281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral wristband
Number of subjects: 40
Study 26113281 — intervention group
Group type: COMPARATOR
Intervention: Placebo wristband
Number of subjects: 40
Study 26113281 — intervention group
Group type: COMPARATOR
Intervention: No wristband
Number of subjects: 40
Study 23803591 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol/hydrochlorothiazide 5/6.25 mg (n=89; R)
Number of subjects: 183
Study 23803591 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine/valsartan 5/160 mg (n=94; E)
Number of subjects: 183
Study 23803591 — intervention group
Group type: COMPARATOR
Intervention: Comparison of R vs E
Number of subjects: 183
Study 21561347 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342
Study 21561347 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 342
Study 19572934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) regional caffeine at 10 mg/kg
Number of subjects: 17
Study 19572934 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic caffeine at 10 mg/kg
Number of subjects: 17
Study 19572934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16511940 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating syringe
Number of subjects: 32
Study 16511940 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 32
Study 15497669 — intervention group
Group type: COMPARATOR
Intervention: 50 mg losartan tablets (Sarvas)
Number of subjects: 24
Study 15497669 — intervention group
Group type: COMPARATOR
Intervention: losartan/hydrochlorothiazide (50 mg/12.5 mg) (Sarvastan)
Number of subjects: 24
Study 15497669 — intervention group
Group type: COMPARATOR
Intervention: E3174 (metabolite of losartan)
Number of subjects: 24
Study 15497669 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 24
Study 11673925 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage (n=45)
Number of subjects: 77
Study 11673925 — intervention group
Group type: COMPARATOR
Intervention: No suction drainage (n=32)
Number of subjects: 77
Study 9624069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 438
Study 8164026 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin applied to half of the back for 6 months
Number of subjects: 5
Study 8164026 — intervention group
Group type: COMPARATOR
Intervention: Untreated nevi
Number of subjects: 5
Study 2452563 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20 mg rscu-PA bolus followed by 60 mg infusion over 1 hour
Number of subjects: 24
Study 2452563 — intervention group
Group type: COMPARATOR
Intervention: Group B: 10 mg rscu-PA bolus followed by 30 mg infusion
Number of subjects: 24
Study 2452563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 80 mg rscu-PA
Number of subjects: 24
Study 29739454 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% L-menthol application
Number of subjects: 17
Study 29739454 — intervention group
Group type: COMPARATOR
Intervention: Control (no menthol application)
Number of subjects: 17
Study 25288372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical vestibular evoked myogenic potential (cVEMP) responses in severe OSAS patients
Number of subjects: 54
Study 25288372 — intervention group
Group type: COMPARATOR
Intervention: Cervical vestibular evoked myogenic potential (cVEMP) responses in control group (snoring without OSAS, AHI <5)
Number of subjects: 54
Study 23942181 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cell transplantation
Number of subjects: 40
Study 23942181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 21600759 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (150 mg/m²/day for 7 days every 2 weeks)
Number of subjects: 859
Study 21600759 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m²/day on day 1 every 3 weeks)
Number of subjects: 859
Study 21600759 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 859
Study 21600759 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 859
Study 17875806 — intervention group
Group type: EXPERIMENTAL
Intervention: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide (100 mg per day during 6 months) (arm B)
Number of subjects: 195
Study 17875806 — intervention group
Group type: COMPARATOR
Intervention: Tandem autologous stem-cell transplantation (arm A)
Number of subjects: 195
Study 16421420 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (150 mg/m2 for 7 days every other week) and Thalidomide (50 to 400 mg daily)
Number of subjects: 29
Study 15050984 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance EC
Number of subjects: 301
Study 15050984 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 301
Study 10996232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometry (TYMP)
Number of subjects: 31
Study 10996232 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Reflectometry (AR)
Number of subjects: 31
Study 10996232 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined test (TYMP and AR)
Number of subjects: 31
Study 10996232 — intervention group
Group type: COMPARATOR
Intervention: Normal ears (control group)
Number of subjects: 31
Study 10996232 — intervention group
Group type: COMPARATOR
Intervention: Ears with effusion (control group)
Number of subjects: 31
Study 9167375 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma serotonin levels in patients with acute appendicitis
Number of subjects: 95
Study 9167375 — intervention group
Group type: COMPARATOR
Intervention: Plasma serotonin levels in patients with abdominal pain of other etiologies
Number of subjects: 95
Study 9167375 — intervention group
Group type: COMPARATOR
Intervention: Plasma serotonin levels in healthy controls
Number of subjects: 95
Study 1362556 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone 0.4 mg tid (young)
Number of subjects: 0
Study 1362556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (young and elderly)
Number of subjects: 0
Study 1362556 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone 0.1 mg and 0.2 mg tid (elderly)
Number of subjects: 0
Study 3104448 — intervention group
Group type: EXPERIMENTAL
Intervention: Camcolit‐400
Number of subjects: 0
Study 3104448 — intervention group
Group type: EXPERIMENTAL
Intervention: Priadel
Number of subjects: 0
Study 3104448 — intervention group
Group type: EXPERIMENTAL
Intervention: New micro‐encapsulated formulation
Number of subjects: 0
Study 3104448 — intervention group
Group type: EXPERIMENTAL
Intervention: Liskonum
Number of subjects: 0
Study 3104448 — intervention group
Group type: EXPERIMENTAL
Intervention: Litarex
Number of subjects: 0
Study 3104448 — intervention group
Group type: COMPARATOR
Intervention: All 5 preparations
Number of subjects: 0
Study 28585182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lime powder (LP) treatment for 6 months
Number of subjects: 80
Study 28585182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27270470 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed power training for knee extensors (12 weeks)
Number of subjects: 40
Study 27270470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 23604058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternotomy
Number of subjects: 111
Study 23604058 — intervention group
Group type: COMPARATOR
Intervention: Pericardial drainage and wash-out
Number of subjects: 111
Study 23121440 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural grass
Number of subjects: 13
Study 23121440 — intervention group
Group type: COMPARATOR
Intervention: Artificial turf
Number of subjects: 13
Study 20131302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 84
Study 20131302 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 84
Study 18427313 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-endoscopic posterior foraminotomy
Number of subjects: 175
Study 18427313 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgical anterior cervical discectomy
Number of subjects: 175
Study 16365061 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g FOS
Number of subjects: 34
Study 16365061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12860366 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 67
Study 12860366 — intervention group
Group type: COMPARATOR
Intervention: Observation-only control group
Number of subjects: 67
Study 11299572 — intervention group
Group type: EXPERIMENTAL
Intervention: Larval debridement therapy (LDT)
Number of subjects: 12
Study 11299572 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel dressings (control)
Number of subjects: 12
Study 9058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.56 mg per day
Number of subjects: 30
Study 9058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.28 mg per day
Number of subjects: 30
Study 9058684 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand azelastine use
Number of subjects: 30
Study 9058684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8364018 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 50 mg BID
Number of subjects: 9
Study 8364018 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 100 mg BID
Number of subjects: 9
Study 8364018 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg BID
Number of subjects: 9
Study 8364018 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 9
Study 3539127 — intervention group
Group type: EXPERIMENTAL
Intervention: lonazolac 300 mg b.i.d.
Number of subjects: 9
Study 3539127 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin 75 mg b.i.d.
Number of subjects: 9
Study 3539127 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 29952839 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP)
Number of subjects: 10
Study 29952839 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (0 mm Hg)
Number of subjects: 10
Study 28965068 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 203
Study 25917060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg)
Number of subjects: 152
Study 25917060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 24749843 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Number of subjects: 0
Study 24749843 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorouracil cream
Number of subjects: 0
Study 24749843 — intervention group
Group type: COMPARATOR
Intervention: MAL-PDT
Number of subjects: 0
Study 23355301 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline (1 to 60 mg, infused over 1-2 hours)
Number of subjects: 36
Study 20149236 — intervention group
Group type: EXPERIMENTAL
Intervention: ESCAPE-knee pain rehabilitation programme
Number of subjects: 29
Study 19026238 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated road environment training program
Number of subjects: 0
Study 19026238 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16901888 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, tailored physical activity intervention with a booster phone call 2 weeks later
Number of subjects: 287
Study 12789232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (2-week course)
Number of subjects: 25
Study 12789232 — intervention group
Group type: COMPARATOR
Intervention: Moderate-to-severe asthma
Number of subjects: 25
Study 12789232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 25
Study 12789232 — intervention group
Group type: COMPARATOR
Intervention: All asthma groups
Number of subjects: 25
Study 12498543 — intervention group
Group type: COMPARATOR
Intervention: 90‐min resting preoxygenation control
Number of subjects: 60
Study 12498543 — intervention group
Group type: COMPARATOR
Intervention: 240‐min resting preoxygenation control
Number of subjects: 60
Study 12498543 — intervention group
Group type: EXPERIMENTAL
Intervention: 90‐min preoxygenation including exercise during the first 15 min
Number of subjects: 60
Study 10523461 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemia control
Number of subjects: 0
Study 10523461 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 0
Study 10523461 — intervention group
Group type: EXPERIMENTAL
Intervention: Particular therapy
Number of subjects: 0
Study 8821611 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (tripotassium dicitrato bismuthate 120 mg qds+tetracycline 500 mg qds+metronidazole 400 mg qds)
Number of subjects: 60
Study 8821611 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy A (triple therapy+omeprazole 20 mg od)
Number of subjects: 60
Study 8821611 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy B (triple therapy+omeprazole 40 mg od)
Number of subjects: 60
Study 2031678 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane film (Opsite)
Number of subjects: 55
Study 2031678 — intervention group
Group type: COMPARATOR
Intervention: Impregnated gauze (Jelonet)
Number of subjects: 55
Study 7152081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% diflorasone diacetate ointment applied once daily
Number of subjects: 60
Study 7152081 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate ointment applied twice daily
Number of subjects: 60
Study 3932648 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/0 polypropylene (Prolene) suture
Number of subjects: 111
Study 3932648 — intervention group
Group type: COMPARATOR
Intervention: Polydioxanone (PDS) suture
Number of subjects: 111
Study 3932648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Prolene and PDS)
Number of subjects: 111
Study 31977825 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty (TSA)
Number of subjects: 124
Study 31977825 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 124
Study 31977825 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse TSA for type-C2 fractures
Number of subjects: 124
Study 31977825 — intervention group
Group type: COMPARATOR
Intervention: ORIF for type-C2 fractures
Number of subjects: 124
Study 31977825 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse TSA for type-B2 fractures
Number of subjects: 124
Study 31977825 — intervention group
Group type: COMPARATOR
Intervention: ORIF for type-B2 fractures
Number of subjects: 124
Study 29189662 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified group with suction drains (remained in place until 12 hours after surgery)
Number of subjects: 120
Study 29189662 — intervention group
Group type: COMPARATOR
Intervention: Standard group (no suction drains)
Number of subjects: 120